Repeated molecular genetic analysis in Brugada syndrome revealed a novel disease-associated large deletion in the SCN5A gene  by Broendberg, Anders Krogh et al.
Repeated molecular genetic analysis in Brugada syndrome
revealed a novel disease-associated large deletion in the
SCN5A gene
Anders Krogh Broendberg, MD,* Lisbeth Noerum Pedersen, MSc, PhD,†
Jens Cosedis Nielsen, MD, DMSc, PhD,* Henrik Kjaerulf Jensen, MD, DMSc, PhD*
From the *Department of Cardiology and †Department of Molecular Medicine, Aarhus University Hospital,
Aarhus, Denmark.Introduction
Brugada syndrome (BrS) is a rare inherited cardiac disorder
with a structurally normal heart.1 The disease is associated
with a severe outcome including syncope, cardiac arrest, and
sudden cardiac death despite low penetrance and variable
expressivity.2 Electrocardiogram (ECG) characteristics of
BrS are divided into 3 different types. Only type 1, with a
prominent coved ST-segment elevation ofZ2 mm followed
by a negative T wave in the right precordial leads (V1–V3), is
diagnostic for BrS. Type 2 and 3 patterns demonstrate an
ST-segment elevation of 2 mm and 1 mm, respectively,
followed by a descending ST slope and a positive T wave,
thereby forming a saddleback conﬁguration. These ECG
characteristics might be either concealed or intermittent.3
More than 300 mutations in 17 genes have been asso-
ciated with BrS. The single most important gene is SCN5A,
with an incidence of 11%–24%. BrS subtypes 2–17 are rare,
with a very low incidence.4 The molecular genetic diagnostic
yield is therefore relatively low and only one third are
successfully genotyped.5 This case report underlines the
importance of repeated genetic screening with multiplex
ligation–dependent probe ampliﬁcation (MLPA) in patients
previously tested with routine Sanger DNA sequencing.
Detection of large genomic rearrangements can be highly
beneﬁcial in further family evaluation of close relatives.Case report
A 27-year-old man (II-1) was referred to the hospital in 2004
after a severe syncope during rest (Figure 1). Previously,
he had experienced 2 episodes of syncope at rest, but without
making contact to the health care system.KEYWORDS Brugada syndrome; MLPA; SCN5A; Ventricular ﬁbrillation
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Transthoracic echocardiography showed a structurally normal
heart and the coronary angiogram demonstrated normal coronary
arteries. An electrophysiological study was performed without
inducible sustained supraventricular or ventricular arrhythmias.
There was no family history of arrhythmias, syncope, or sudden
cardiac death. After informed consent an implantable
cardioverter-deﬁbrillator (ICD) was implanted. Within 6 months
after ICD implantation 3 appropriate ICD therapies on ventricular
ﬁbrillation were observed (Figure 2B). At that time DNA Sanger
sequencing revealed no mutations in the SCN5A gene.
Nine years later the index patient’s 7-year-old son (III-2)
was diagnosed with attention deﬁcit–hyperactivity disorder
(ADHD) and needed medical treatment (Figure 1). His
baseline ECG showed a slight ST-segment elevation in leads
V1 and V2, which raised the suspicion of BrS (Figure 2C).
However, the observed ECG changes were not diagnostic for
BrS. Before medical treatment for ADHD was initiated, we
decided to repeat the molecular genetic analysis of the
SCN5A gene, including MLPA for detection of large
genomic deletions or insertions.
Surprisingly, the index patient (II-1) was now identiﬁed
heterozygous for a deletion of exon 23, while the son (III-2)
had 2 intact alleles. Mutations in the SCN5A gene that are
linked to BrS are scattered throughout the entire gene. Exon
23 of the SCN5A gene encompasses bases 3841–3963
(NM_198056.2), corresponding to codons 1281–1321. The
probe for exon 23 of the SCN5A gene binds at nucleotide
3872–3947, meaning that it spans almost the entire exon, and
that breakpoints probably are located in the ﬂanking introns.
The exact locations of the breakpoints were not established.
The deletion affects S3–S4/S5 of domain III of the protein.
It is highly plausible that the transcripts that may be
produced by the truncated allele are subject to nonsense-
mediated RNA decay, leaving the affected patient with
haploinsufﬁciency regarding SCN5A, causing BrS.
Cascade screening of relatives was established in accord-
ance with international guidelines.6 We found that the father
(I-1) and both sisters (II-2 and II-3) carried the deletion,pen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Molecular genetic testing including multiplex
ligation–dependent probe ampliﬁcation is
important to identify large genomic
rearrangements.
 Large genomic rearrangements in the SCN5A gene
are very rare.
 Disease penetrance in Brugada syndrome is low.
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SCN5A deletion–positive relatives had normal ECGs and
echocardiograms, and ﬂecainide testing did not reveal a
diagnostic Brugada pattern. All 3 relatives were offered
annual follow-upwithout ICD and after 28 months of follow-up
they remain asymptomatic.
Molecular genetic analysis
DNA was extracted from leukocytes. Screening for mutations
in the SCN5A gene including all exons and exon–intron
boundaries was performed with the LightScanner (Bioﬁre
Diagnostic Inc., Salt Lake City, Utah), unlabeled primers, and
the intercalating ﬂuorescent dye LCGreen. Sanger sequencing
of exons with aberrant melting patterns was performed using
BigDye v1.1 (Applied Biosystems, Foster City, California)
and Genetic Analyzer 3130XL (Applied Biosystems, Foster
City, California). Sequences were interrogated/queried with
Gensearch v4.0 (Phenosystems, Wallonia, Belgium) or
Sequencer v5.0 (Gene Codes Corporation, Ann Arbor,
Michigan) software. Primer sequences for Sanger sequencing
were partly designed by Millat et al7 and partly designed in
house, and are available upon request.
For detection of large genomic deletions or insertions
MLPA was performed with the SALSA MLPA probe mix
P108-B2 SCN5A (MRC Holland, Amsterdam, The Nether-
lands), which holds probes for all exons from 1b through 29Figure 1 Family pedigree. Index patient is marked with an arrow.(NM_198056.2). Results were analyzed with GeneMapper
software (Applied Biosystems, Foster City, California), and
deviations from 2 reference samples were assessed by MAQ-
S software (Multiplicom, Niel, Belgium).
Discussion
Genetic testing in cardiac arrhythmias has been widely used
during the past couple of decades. MLPA, however, has not
been part of the routine practice in most laboratories world-
wide until recently. Since September 2009 we have tested all
samples received for BrS testing as well as testing other
inherited cardiac arrhythmias for large deletions/duplica-
tions, using MLPA. No large gene rearrangements in
SCN5A were found until the present case.
The index patient presents a malignant Brugada pheno-
type, but the penetrance in the family is surprisingly very
low. Despite carrying a large SCN5A deletion, which
encompasses more than an entire exon, the relatives do not
exhibit a Brugada phenotype. However, low disease pene-
trance is not a unique feature of BrS, and is also well known
in other channelopathies like long QT syndrome (LQTS).8
Mutations in the alpha subunit of the voltage-gated sodium
channel (SCN5A) are a well-known cause of both hereditary
LQTS and BrS. Where the mutations causing LQTS induce
gain of function of the protein, mutations causing BrS induce
loss of function.9 The most common genetic alterations in the
SCN5A gene are missense mutations, followed by nonsense,
frameshift, and splice-site mutations. Large deletions/inser-
tions are extremely rare worldwide.10
Others have documented the rarity of large deletions/
duplications. In a Dutch study, 38 SCN5A mutation–negative
index patients were investigated for exon duplications and
deletions without detection of large genomic rearrange-
ments.11 Recently, a similar study on 37 Spanish BrS patients
was performed without discovering large gene rearrange-
ments.12 Other groups have documented the presence of large
deletions in the SCN5A gene, but these cases are rare.13–15
Although the presence of large deletions/insertions in
SCN5A has been reported before, this case emphasizes the
importance of repeated genetic testing with MLPA in
patients with obvious disease phenotypes, even though they
previously have been tested with routine Sanger sequencing
technique. The beneﬁts are clear, and 50% of the relatives are
exonerated from having a disease-causing variant, like the
7-year-old boy described here. Shortly after genetic testing,
the boy could start his much-needed medication for ADHD
without an increased risk of life-threatening arrhythmias.
Conclusion
If routine molecular genetic testing is limited to DNA
sequencing, ﬁndings of large genomic deletions/insertions
will continue to be rare, leading to under-diagnosis of
hereditary arrhythmia cases as BrS. Repeated DNA analysis
with addition of the MLPA technique is beneﬁcial and
increases the diagnostic yield of molecular genetic variants
causing BrS.
Figure 2 A: A 12-lead electrocardiogram (ECG) from the index patient with type 1 pattern diagnostic for Brugada syndrome. B: Implantable cardioverter-
deﬁbrillator (ICD) interrogation in the index patient, with ventricular ﬁbrillation eliciting appropriate and effective ICD therapy. C: A 12-lead ECG from the son
of the index patient.
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